Phase 3 Trial of AMT-061 Gene Therapy for Hemophilia B Exceeds Target Dosing

Phase 3 Trial of AMT-061 Gene Therapy for Hemophilia B Exceeds Target Dosing

Hemophilia News Today

Image

Please enable the javascript to submit this form

Supported by educational grants from Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, and uniQure, Inc.

Essential SSL